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The idea of using cytotoxic drugs, toxins, or radioisotopes coupled to antibod- 
ies to destroy hidden tumor cells has been revitalized by the development of the 
monoclonal  antibody  (MAb) 1 technology  (1).  Selected  MAb  directed  against 
tumor antigens, with their specificity for single antigenic determinants, appear 
to be  the  ideal carriers  for antitumor agents.  However,  a  prerequisite  for all 
these forms of passive immunotherapy is that the antibodies are capable to reach 
the target tumor cells in vivo. 
We  have  previously reported  encouraging  results  of tumor  localization  by 
immunoscintigraphy in patients with colorectal carcinomas (2, 3) using one MAb 
(MAb 23) directed against carcinoembryonic antigen (CEA) (4, 5). However, the 
amount of radiolabeled  antibody localizing specifically within the tumor mass 
was still relatively low as compared with the amounts of radioactivity remaining 
in the blood pool, reticuloendothelium, and various normal organs (2,  3).  To 
improve these results we recently selected a series of MAb with higher affinities 
for  CEA  than  the  previously  used  MAb  (6)  and  prepared  F(ab')2  and  Fab 
fragments. The fragments of high affinity MAb should give higher tumor uptakes 
with less accumulation in the reticuloendothelium and at the same time a more 
rapid clearance from the circulation. 
For ethical reasons and because tumors are very heterogenous in terms of size, 
anatomical sites, histology, vascularization, etc., it appears inappropriate to screen 
the different MAb and their fragments for best tumor localization in patients. 
The model of nude mice bearing human colon carcinoma xenografts that we 
originally used for testing polyclonal anti-CEA antibodies in  1074 (7) offers the 
advantage of a relatively constant tumor antigen expression and accessibility. 
Other groups have used similar experimental models of xenografted human 
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tumors to test the tumor-localizing capacity of polyclonal and monoclonal anti- 
bodies  directed  against  various  tumor  markers  (8-15),  but  no  systematic 
comparison of different MAb and their fragments against the same marker have 
been reported. Despite the limitations of any experimental model of xenografted 
human tumors, namely the absence of normal human tissue as counterpart of 
the tumor transplant, we feel that these in vivo experiments are necessary for 
the final selection of MAb and fragments before human application. 
The purpose  of this report  is to compare  the tumor localization capacity in 
vivo of four anti-CEA MAb with their F(ab')2 and Fab fragments in nude mice 
bearing human colon carcinoma grafts. The results showed a  dramatic increase 
of specific tumor uptakes of radiolabeled F(ab')~ and Fab fragments as compared 
with intact antibodies and a marked improvement of tumor detection by external 
scanning in this experimental model. 
Materials and Methods 
Production and Screening of Hybridomas.  The derivation of 26  new hybridomas that 
secrete anti-CEA antibodies and their in vitro selection is described in detail elsewhere 
(6). Briefly, a BALB/c mouse was injected intraperitonally with 15 ~g of purified colon 
carcinoma CEA (16) in complete Freund's adjuvant. After 3 too, the mouse was reinjected 
with 15,  100, and  150 #g of purified CEA in saline at daily intervals (17).  Spleen cells 
collected 6 d after the first boost were used for fusion with the myeloma cell line NSI/ 
lag4.1 (18). 
Hybridoma supernatants were screened for antibody production by a binding assay to 
radiolabeled CEA, using ammonium sulfate precipitation. Supernatants were also screened 
for strong inhibition of this binding by unlabeled CEA and for weak inhibition of this 
binding by a normal glycoprotein present in granulocytes and known to cross-react with 
CEA, called normal glycoprotein (NGP) (19) or nonspecific cross-reacting antigen (NCA) 
(20). Cross-reaction of hybridoma supernatant with granulocyte glycoprotein(s) (21) was 
also  tested by immunoperoxidase staining of frozen sections of primary human colon 
carcinoma using the avidin-biotin system. After this in vitro screening, three new MAb, 
designated 35, 202, and 192, were selected for in vivo testing in parallel with MAb 23, 
which had already been used for tumor detection by immunoscintigraphy in patients (2, 
3). 
Pur~cation and Testing of Selected MAb.  The selected hybrids were cloned by limiting 
7  dilution. Hybridoma ascites were produced by injecting 10  hybrid cells intraperitoneally 
into Pristane (Aldrich, Beerse, Belgium)-primed BALB/c mice. MAb were purified from 
ascites by ammonium sulfate precipitation (45% saturation at 4°C) and DE 52 cellulose 
(Whatman, Balston, England) ion exchange chromatography. The MAb were eluted with 
a gradient of phosphate buffer, 0.01  to 0.15 M, pH 8 (22). A control IgG1 was purified 
by the same procedure, from ascites obtained with myeloma cell line P3×63Ag8 (1). 
The affinities of the four purified MAb for l~I-labeled CEA were determined both in 
0.02 M Tris-HC! buffer, pH 7.4, and in 0.15  M phosphate-buffered saline (PBS) using 
Scatchard Plot and Lineweaver Burke analysis. The affinities in low molarity Tris buffer 
of these four MAb were all in the range of 1.6-6.2 x  101° M-. The affinities in PBS were 
5.8  X  108, 1.1  X  10 9,  6  X  109, and  1.8  x  101° M-  for MAb  23,  202,  35, and  192, 
respectively. By a radioimmunoassay (5) using immobilized CEA and goat antisera against 
mouse immunoglobulin isotypes (Meloy,  Springfield, VA),  it was  shown that the four 
selected MAb were of IgGl subclass. 
Reciprocal binding inhibition tests on insolubilized CEA showed that MAb 23 and 202 
were reacting with the same or closely related epitopes on CEA, and MAb 35 and 192 
were reacting with different epitope.s The four purified MAb were also. tested for binding 
to purified soluble ~I-labeled NCA (20) (Commissariat Energie Atomlque, Gif  sur Yvette, 
France) using ammonium sulfate precipitation, and for binding to the surface of freshly BUCHEGGER ET  AL.  415 
~repared normal  human  granulocytes by an  indirect binding  radioimmunoassay using 
5I-labeled rabbit antibodies against mouse F(ab')2 (23). 
Preparation of  F(ab')2 and Fab Fragments.  F(ab')2 fragments of the four selected purified 
MAb and control IgG were obtained by incubation for 22 h at 370C with 5% (wt/wt) 
pepsine, (Worthington, Freehold N  J) in acetate buffer, pH 4 (24), followed by filtration 
on Sephadex G-150 (Pharmacia, Uppsala,  Sweden). Fab fragments of Mab 202 and 35 
and of control IgG were obtained by incubation for 6  h at 37°C with 2 or 3% (wt/wt) 
papain  (Sigma  Chemical  Co.,  St.  Louis,  MO)  in  a  0.075  M  phosphate  buffer, pH  7, 
containing 0.075  M  NaCI, 0.01  M L-cysteine hydrochloride, and 0.002 M  EDTA (25). 
Fab fragments were separated from partially digested IgG by filtration on Sephadex G- 
150 and from Fc fragments by a DE-52 ion exchange chromatography column equilibrated 
in 0.01 M phosphate buffer, pH 8. The Fab fragments were eluted with the void volume, 
whereas  the  Fc  fragments  were  retained.  Purified intact  MAb,  and  F(ab')2  and  Fab 
fragments  were  analyzed  by  sodium  dodecyl sulfate  (SDS)-polyacrylamide gel  (8.5%) 
electrophoresis. They gave single bands with the expected molecular weights of about 
150,000, 105,000, and 50,000, respectively (Fig.  1). 
The affinities of two  Fab  fragments were measured after labeling with  1251 by the 
following method. First, increasing amounts of labeled Fab were incubated with a constant 
amount of unlabeled CEA. The CEA was then precipitated after incubation with a second, 
noncompetitive, intact Mab by addition of ammonium sulfate. The affinities in 0.02 M 
Tris buffer were 6.7 ×  109 and 9.3 x  109, and in PBS, 4.1  x  109 and 1.1  x  10  s M-, for 
Fab of Mab 192 and 202, respectively. 
Iodine Labeling of Intact lgG and of Their Fragments.  20 #g of purified MAb or of their 
fragments were labeled with 1 mCi of ~31I using the Iodobeads method (Pierce Chemicals, 
Rockford, IL). Control IgG or its fragments were labeled under the same conditions with 
~5I. Free iodine was removed from the labeled proteins by dialysis or by Sephadex G-25 
chromatography. The specific radioactivity ranged from 20 to 40 ~Ci/~g of MAb for 
both isotopes. Labeled antibodies or their fragments were tested for binding activity by 
overnight incubation in 0.15 M PBS at 25 °C with 10 #g CEA bound to cyanogen bromide 
(CNBr)-activated Sepharose 4B (Pharmacia,). 
Injection of Nude Mice Bearing Grafts of Human  Colon Carcinoma.  The human  colon 
carcinoma (Co-112) (7)  maintained  by serial  transplantations into BALB/c nude mice 
produces  CEA  as  demonstrated  using  immunoperoxidase  (26).  Transplanted  tumors 
contain 50-100 #g CEA/g whereas sera from mice bearing tumors of ~  1 g contain 5- 
20 ng of CEA per ml of serum as determined by an enzyme immunoassay using anti-CEA 
Mab (27). Mice having tumors of 0.1-1.5 g  (2-4 wk after transplantation) were chosen 
131-1  t  for localization experiments. 200 #Ci of  I-labeled Mab or F(ab )2 fragments and 300 
#Ci of  labeled Fab fragments, representing 5-10 #g of  protein, were injected intravenously 
together with 80 #Ci of ~25I-iabeled control IgG or its fragment, representing 2-4 #g of 
protein. The thyroids of the mice were blocked by addition of iodine (Lugol) solution in 
FIGURE  1.  SDS-polyacrylamide  gel (8.5%) electrophoresis of purified MAb 35 and 202 and 
their fragments. (A) intact 35, (B) F(ab')2 35, (C) Fab 35, (D) Fab 202, (E) F(ab')2 202, (F) 
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the drinking water. 
Scanning and Dissection of Injected Animals.  Whole-body scannings of mice anesthesized 
with Tribromoethanol (Merck,  Mfinchen, Federal Republic of Germany [FRG])  were 
obtained by using a thyroid scanning unit (Picker Magnascanner 500) with a 131i collimator. 
After preliminary scanning studies performed at different times, we selected day 3 after 
injection for intact MAb and day 2 for both types of fragments as the best times for 
systematic comparison of scannings. Similarly, days 4-5 for intact MAb, day 3 for F(ab')2, 
and day 2-3 for Fab were chosen for dissection of the animals and direct measurement 
of the radioactivity in the different organs. The mice were killed by ether anesthesia and 
0.5 ml of blood was taken from the vena cava. The tumor as well as all different organs 
including head and carcass were dissected, weighed, and counted for both iodine isotopes 
in a dual channel gamma counter. After differential radioactivity analysis, antibody and 
normal  IgG  concentrations were  expressed  in  percentages  of the  total  radioactivity 
recovered.  Antibody and normal  IgG (NIgG)  uptakes into tumor were calculated by 
dividing the radioactivity concentration in the tumor by the corresponding concentration 
in  individual normal organs or in the whole mouse (without the tumor).  Finally, the 
specificity index of tumor localization was calculated by dividing the antibody uptake into 
the tumor by the normal IgG uptake according to the following formula: (MAb in tumor/ 
MAb in normal tissue)/(NIgG in tumor/NIgG in normal tissue). 
Autoradiography.  The histological distribution of injected, radiolabeled MAb in tumors 
was analyzed by autoradiography. Mice  bearing the  tumor Co-112  (7)  were  injected 
intravenously with *~SI-labeled MAb or fragments, or with control IgG (160 ~Ci for intact 
MAb or F(ab')~ fragments and 240 t~Ci for Fab fragments corresponding to 5-10 #g of 
proteins). The mice were sacrificed the 4th d after injection of intact MAb and the 2nd d 
after injection of fragments. Half  of the resected tumors were fixed in 2.5% glutaraldehyde 
and embedded in methacrylate, the other half were frozen in isopentane cooled by liquid 
nitrogen. Sections of 2 t~m for methacrylate-embedded tumors and of 8 ~m for frozen 
tumors were dipped in Ilford Nuclear Emulsion type L 4 (Ilford, Essex, UK) and developed 
2-4 mo later. Tissue sections were stained with nuclear fast red (Merck, Darmstadt, FRG). 
The CEA present in the same tumor was assessed by immunoperoxidase staining of the 
frozen section using MAb anti-CEA and the avidin-biotin system (26). These sections were 
counterstained with Gill's hematoxylin (Polysciences, Warrington, PA). 
Results 
In Vitro Selection and Testing of Intact MAb and Fragments.  Four anti-CEA MAb 
were selected for the present study on the basis of the following criteria:  MAb 
35 showed the highest specificity for CEA with no cross-reaction with NCA and 
no binding to human granulocytes. MAb  192  was selected because of its high 
affinity for CEA in physiologic molarity buffer (1.8  x  101°  M-).  However,  its 
cross-reaction with NCA and human granulocytes would limit its use in human 
immunoscintigraphy. MAb 202  was taken because  it appears  to recognize the 
same epitope on CEA as the previously used MAb 23 but had a  higher affinity 
in physiologic molarity buffer. MAb 23 had been used for immunoscintigraphy 
in patients with encouraging results and therefore served here as reference. MAb 
202 and 23 did not bind to purified radiolabeled NCA, but both bound to the 
surface of granulocytes. 
The percentages of binding of the radiolabeled, intact MAb, and their F(ab')2 
and Fab fragments to CEA immobilized on CNBr-activated Sepharose, obtained 
in PBS are shown in Table I. They ranged between 50 and 78%  for MAb and 
their fragments. Labeled control normal IgG and fragments gave 2.3-6.4%  of 
binding to the same CEA-Sepharose. 
Tumor Localization of MAb Studied by Paired Labeling Experiments.  Groups of 4- BUCHEGGER  ET  AL.  417 
TABLE  I 
Percentages of Binding of Radiolabeled MAb and Fragments to CEA 
Coupled to Sepha rose 
MAb  Control IgG  MAb form 
35  192  202  23  (P3×63Ag8) 
Intact  70 (2.1)*  67 (3.6)  78 (4.0)  58 (1.9)  6.4 
F(ab')2  77 (2.6)  67 (2.9)  76 (3.2)  54 (3.2)  3.5 
Fab  65 (5.5)  ND  50 (4.1)  ND  2.3 
* Percentage  of antibody radioactivity bound  to  CEA-Sepharose  is fol- 
lowed by the individual background value (in parenthesis) obtained for 
each MAb or fragment with Sepharose containing bovine serum albu- 
min. ND, not done. 
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FIGURE 2.  Distribution of MAb 35 or its fragments and control  IgG or fragments injected 
simultaneously into nude mice bearing  grafts of a human  carcinoma. The concentration  of 
antibody  (shaded  bars) and  control  IgG (open  bars)  per  gram of tissue  is expressed  in 
percentages of total specific radioactivity recovered at various times after injection as indicated 
in the text. The vertical lines represent the standard deviations calculated from groups of four 
to seven animals per  MAb or  fragment.  T,  tumor;  S,  spleen; Li,  liver; K,  kidneys; GI, 
gastrointestinal tract; H, heart; Lu, lungs; SG, salivary glands; C, carcass and head; B, blood. 
7 nude mice bearing grafts of the human colon carcinoma Co-112 were injected 
simultaneously with  ~3~I-labeled MAb or their fragments and with their normal 
IgG counterpart labeled with l~SI, and were dissected 2-5 d  later. The results of 
antibody and normal IgG concentrations per gram of tumors and normal organs 
(expressed  in  percentage  of total  radioactivity recovered for each  isotope) are 
shown in Figs.  2-5.  The tumor uptakes for antibody and normal IgG calculated 
by comparison  with  individual  normal  organs  and  with  the  whole  mouse  are 
shown in Fig. 6. The specificity indices of tumor localization compared with the 
whole animal are shown in Table II. 
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ranged between 7 and  15 and the specificity indices between 3.4 and 6.8. The 
lowest  values  were  obtained  with  MAb  35  and  the  highest  with  MAb  202. 
Compared  with  intact  MAb,  the  F(ab')2  fragments gave  markedly increased 
tumor uptakes with values ranging between 12 and 24, as well as higher specificity 
indices, ranging between 5.3 and 8.2. The highest results for F(ab')~ fragments 
were observed with MAb 35 followed by MAb 202. 
Fab fragments from the two most promising MAb (clone 35  and 202)  were BUCHEGGER  ET  AL.  419 
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prepared and tested. They both gave very high tumor uptakes of 34 and 82, and 
specificity indices of 12 and 19, for Fab 202 and 35, respectively. It is interesting 
that the Fab fragment of MAb 35 gave the best results, because MAb 35 is also 
the most specific anti-CEA MAb, since it does not cross-react with granulocyte 
glycoprotein(s). 
The specificity indices calculated for different organs (data not shown) were 
rather constant for one type of MAb or fragment and consequently very close 
to the mean values shown in Table II. The stability of these specificity indices is 
also reflected by the fact that tumor uptakes of antibodies plotted against those 
of control  IgG  fall  on  a  straight  line,  whose  slope  is  the  expression  of the 
specificity of tumor localization (Fig. 6). Tumor uptakes can show large variations 
in  relation to  the degree of vascularization of different organs but specificity 
indices are more constant and thus represent more meaningful values. 
The marked increase of tumor uptakes and specificity indices observed with 
MAb fragments is in part due to their more rapid elimination, as shown by the 
decrease of concentration  of recovered radioactivity from  the  whole animal 
(Table  III.)  The absolute  concentration of fragments in  tumors was also  de- 
creased (as compared to intact MAb) but to a lesser degree than their concentra- 
tion in normal tissues (Table III). 
External Scanning Studies.  Intact MAb gave clear tumor detection by scanning 
only 3 d after injection, for relatively large tumors of 0.5-1  g as shown in Fig. 
7A.  The  failure to  detect tumors of smaller size or at  earlier times was  due 
mostly to the abundance of labeled intact MAb in the blood and thus in the well- 
vascularized organs, as determined in a  few animals sacrificed and dissected at 
day 2 and 3 (data not shown), and by the results obtained at day 4-5 (Fig. 2-5). 
F(ab')~ fragments gave earlier positive tumor detection at day 2  (Fig.  7B) but 
these fragments did not give very contrasted scannings for tumors smaller than 420  TUMOR  LOCALIZATION  OF  FRAGMENTS  OF  MONOCLONAL  ANTIBODIES   .c..b3s  I  .c..b,o, 
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FIGURE 6.  Tumor uptakes of MAb or fragments (ordinate) plotted against those of normal 
IgG or fragments (abscissa).  Tumor uptakes  were calculated by comparison with the whole 
mouse without the tumor (fia), carcass (C),  liver (Li),  blood (B), and kidneys (K).  First panel: 
Results obtained with MAb 35. Fab fragment (O), F(ab')2 fragment (&), and intact MAb (O). 
Panels 2-4: Similar analysis of MAb 202, 23, and 192, respectively, and their fragments. The 
slope of the straight line joining the zero of the two axes with the tumor uptake obtained by 
comparison with the whole mouse (ill) is the expression of the specificity of tumor localization. 
0.5g. 
The best scanning results were obtained with Fab fragments which allowed 
the clear detection of tumors weighing only 0.1-0.3  g  2 d  after injection (Fig. 
7, C and D). It should be noted that all scanning pictures shown represent raw 
data without any computerized background subtraction. 
Autoradiographs of Tumor Sections.  Autoradiographs demonstrate that injected 
labeled MAb and fragments localized in tumor nodules and not in the stromai 
connective tissue of mouse origin, as shown for intact MAb (Fig. 8A). However, BUCHEGGER  ET  AL. 
TABLE II 
Spec~city Indices of Tumor Localization Obtained with Intact MAb and 
Fragments 
421 
MAb 
MAb form 
35  192  202  23 
Intact  3.4 ± 0.7*  3.6 ± 0.3  6.8 ± 2.7  5.0 ± 0.7 
F(ab')2  8.2 ± 5.7  7.5 ± 5.0  7.9 ± 3.3  5.3 ±  1.3 
Fab  19.0 ± 5.5  ND  11.9 ± 4.3  ND 
* The specificity indices ±  the  standard  deviation  were  calculated  by 
comparison with the normal tissue of the whole mouse according to the 
formula given in Materials and Methods. ND, not done. 
TABLE  III 
Absolute Concentration of Antibody Radioactivity Recovered in Tumors and in Whole Mice 
MAb  MAb form  Tumor  Mouse normal tissues 
MAb 35 
MAb 202 
Intact  (day 4-5)*  18.2 _ 6.3' (9.1)  e  2.61_+0.46'(1.31) 0 
F(ab')2 (day 3)  4.9 _+ 2.5  (2.5)  0.20 -  0.03  (0.10) 
Fab  (day 2-3)  7.5 _  1.2  (2.5)  0.09 + 0.02  (0.03) 
Intact  (day 4-5)  9.1 ± 2.5  (4.5)  0.58 ± 0.20  (0.29) 
F(ab')2 (day 3)  3.4 ± 1.0  (1.7)  0.15 ± 0.06  (0.08) 
Fab  (day 2-3)  2.9 ± 1.3  (1.0)  0.09 ± 0.02  (0.03) 
* Days of dissection and counting. 
* Absolute concentration  of antibody radioactivity recovered in ~Ci/g of tissues _  standard 
deviation (corrected for physical half-life of isq). 
a Concentration  of antibody radioactivity recovered per gram of tissue expressed in percent 
of injected dose (corrected for physical half-life of zslI). 
the labeled intact MAb were not distributed homogeneously in the entire tumor 
tissue. There were areas of intense concentration of radioactivity in nonnecrotic 
tumor tissue,  whereas other areas morphologically very similar contained much 
less  radioactivity.  The  high  concentration  of radioactivity  at  the  periphery  of 
tumor nodules suggests that the vascularization was an important factor for this 
antibody  distribution.  In  contrast,  necrotic  areas  of the  tumor  showed  diffuse 
and very low concentrations of radioactivity. 
Labeled  F(ab')~  and  Fab  fragments  appeared  to  penetrate  deeper  into  the 
tumor nodules and to concentrate  in the pseudolumen of the malignant glands 
(Fig.  8, B and C) that contained the highest concentration  of CEA, as shown by 
in  vitro  immunoperoxidase  staining  on  frozen  sections  from  the  same  tumor 
(Fig.  8D).  Mice  injected  with  labeled control  normal  IgG or fragment showed 
very low diffuse radioactivity in the tumor (data not shown). 
Discussion 
We describe herein the first thorough comparative study of tumor localization 
in  vivo of intact  MAb  and  their  F(ab')~ and  Fab fragments directed  against  a 
tumor-associated antigen. Radiolabeled fragments, in particular Fab, gave much 
higher tumor uptakes and better tumor detection by external scanning than did 
intact MAb in the model of nude mice grafted with a human colon carcinoma. 
This experimental model was chosen because human colon carcinomas grafted 422  TUMOR  LOCALIZATION  OF  FRAGMENTS OF  MONOCLONAL  ANTIBODIES 
FIGURE  7.  Whole-body  scannings of nude mice bearing grafts of a human colon carcinoma 
obtained after intravenous injection of In'I-labeled MAb or fragments. (A) Mouse injected with 
intact MAb 202; tumor weighing 1 g, scan obtained at day 3 after injection. (B) MAb 202 
F(ab')2 fragment, tumor of 0.7 g~ scan at day 2. (C) MAb 202 Fab fragment, tumor of 0.3 g, 
scan at day 2. (D) MAb 35 Fab fragment, tumor of 0.1 g, scan at day 2. Scans shown at the 
right of the corresponding mice represent raw data without any background subtraction. 
in  nude  mice  retain  the  same  histological  morphology as  the  primary  human 
tumor (28),  and  synthetize and  release  CEA  (7),  as  observed in  patients.  The 
specificity  of  the  results  was  assessed  by  using  the  paired  labeling  method 
described by Pressman et al. (29) in which a  control mouse IgG or its fragments 
labeled  with  1~5I is  injected  simultaneously  with  the  13~I-labeled  MAb.  This 
internal control allows one to correct for any nonspecific accumulation of labeled 
proteins in tumor tissues and the calculated specificity indices represent the most 
relevant evaluation  of the  MAb's  capacity  to  bind  to  antigens  present  in  the 
tumor. 
It was of particular interest to evaluate antibody fragments, since our prelim- 
inary clinical results  using  F(ab')2  fragments from our first anti-CEA  MAb  (2) 
and from a MAb directed against another colon carcinoma antigen (30) suggested 
that these fragments  gave less  nonspecific accumulation  of radioactivity in  the C
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 424  TUMOR  LOCALIZATION  OF  FRAGMENTS  OF  MONOCLONAL  ANTIBODIES 
reticuloendothelium than intact MAb. However, clinical results are often difficult 
to interpret since they are derived from the evaluation of photoscanning pictures, 
and direct measurement of radioactivity can be obtained only from surgically 
resected malignant and normal tissues. Thus, the present experimental results 
represent a much stronger argument in favor of using fragments of MAb for the 
detection of tumor in patients.  In particular,  the fragments of MAb 35, which 
gave the highest tumor uptakes and the least cross-reaction with human granu- 
locytes, appear to be the best candidate for localization of colorectai carcinoma 
by immunoscintigraphy in patients. 
Our autoradiographic results confirmed the specificity of tumor localization 
of anti-CEA MAb and fragments at the histological level and differ from those 
of Lewis et al. (31) who reported that radiolabeled intact goat anti-CEA antibodies 
localized in  the stromal  connective tissue  of mouse origin present within  the 
grafted human tumor. Despite their specificity, however, our results provide a 
warning for those who are already considering the use of radiolabeled anti-CEA 
antibodies  for  therapy  (32),  since  the  autoradiographs  show  that  the  labeled 
MAb localized in areas with high CEA concentration but not on all carcinoma 
cells. Therefore if radiotherapy with radiolabeled MAb is considered one should 
select isotopes capable of destroying tumor cells within a radius of 50-100 #m. 
High energy alpha- or beta-emitting isotopes with these properties can be coupled 
to antibodies by metal chelates such as diethylenetriamine pentaacetic acid (33, 
34).  Using this chelate,  we have  recently coupled  llqndium  to  MAb  35  and 
shown that after injection into nude mice, it gave similar tumor uptakes as those 
obtained  with  a3q-labeled  MAb.  Thus,  the  MAb and  the  nude mouse model 
described here should provide a  means to evaluate the possibility of destroying 
human solid tumors by radioimmunotherapy. 
Summary 
Four  monoclonal antibodies  against  carcinoembryonic  antigen  (CEA)  have 
been selected from 32 hybrids that produce antibodies against this antigen, by 
the criteria  of high affinity for CEA and low cross-reactivity with granulocyte 
glycoprotein(s). The specificity of tumor localization in vivo of the four MAb, 
and their F(ab')2 and Fab fragments was compared in nude mice bearing grafts 
of a serially transplanted, CEA-producing, human colon carcinoma. The distri- 
bution of radiolabeled MAb and their fragments after intravenous injection was 
analyzed by direct measurement of radioactivity in tumor and normal organs, as 
well as by whole-body scanning and by autoradiography of tumor sections. Paired 
labeling experiments, in which l sa I-labeled antibody or fragments and l~SI-labeled 
control  IgG  are  injected  simultaneously,  were  undertaken  to  determine  the 
relative  tumor uptakes  of each  labeled  protein.  The  tumor antibody  uptake 
divided by that of control IgG defines the specificity index of localization. Tumor 
antibody uptakes (as compared with the whole mouse), ranging between 7 and 
15, and specificity indices ranging between 3.4 and 6.8, were obtained with the 
four intact MAb at day 4-5 after injection. With F(ab')2 fragments of the four 
MAb, at day 3, the tumor antibody uptakes ranged between  12 and 24 and the 
specificity indices between 5.3 and 8.2. With the Fab fragments prepared from 
the two most promising MAb, the antibody uptakes reached values of 34 and 82 BUCHEGGER ET  AL.  425 
at day 2-3 and the specificity indices were as high as  12 and 19.  The scanning 
results paralleled those obtained by direct measurement of radioactivity. With 
intact MAb, tumor grafts of 0.5-1 g gave very contrasted positive scans 3 d after 
injection. Using MAb fragments, tumors of smaller size were detectable earlier. 
The best results were obtained with Fab fragments of MAb 35, which gave clear 
detections  of  tumors  weighing  only  0.1  g  as  early  as  48  h  after  injection. 
Autoradiographs of tumor sections from mice  injected with  125I-labeled  MAb 
demonstrated that the radioactivity was localized in the tumor tissues and not in 
the stromal connective tissue of mouse origin. The highest radioactivity concen- 
tration was localized in areas known to contain CEA such as the pseudolumen of 
glands and the apical side of carcinoma cells. The penetration of radioactivity in 
the central part of tumor nodules and the pseudolumen appeared to be increased 
with the use of MAb fragments. 
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